Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Not yet recruiting 1Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 7Thoracic 2Tumor-Agnostic 1Sarcoma 1

Conditions

Neoplasms 1

Interventions

Standard of Care 4Radiotherapy 4Oxaliplatin 4tislelizumab 3anlotinib 2Radiation 2Paclitaxel 2Capecitabine 2130-nm albumin-bound paclitaxel 2vedolizumab 1trastuzumab deruxtecan 1trametinib 1toripalimab 1surufatinib 1pembrolizumab 1ivosidenib 1disitamab vedotin 1coenzyme Q10 1cemiplimab 1blinatumomab 1Whole Genome Sequencing 1Ursodeoxycholic Acid 1Ultrasonography 1Tretinoin 1Thymopentin 1Surgical Procedures, Operative 1Sequence Analysis, RNA 1Respiratory Rate 1Radiotherapy, Intensity-Modulated 1Radiosurgery 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Not yet recruiting × surufatinib × Tumor-Agnostic × Clear all
NCT07279532 2025-12-12

Clinical Study of Adjuvant Surufatinib Therapy for Postoperative High-risk Neuroendocrine Tumors Based on the Ninth Edition of the AJCC Staging System

Second Affiliated Hospital, School of Medicine, Zhejiang University

Phase 2 Not yet recruiting
35 enrolled
Tumor-Agnostic

Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡